Your browser doesn't support javascript.
Detection of Antibodies Against the SARS-CoV-2 Spike Protein and Analysis of the Peripheral Blood Mononuclear Cell Transcriptomic Profile, 15 Years After Recovery From SARS.
Zhao, Lili; Han, Na; Zheng, Yali; Rao, Huiying; Li, Jia; Chen, Yanwen; Yu, Bing; Xu, Yu; Chen, Hongsong; Gao, Zhancheng; Jiang, Baoguo.
  • Zhao L; Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
  • Han N; Department of Central Laboratory, Peking University People's Hospital, Beijing, China.
  • Zheng Y; Department of Respiratory and Critical Care Medicine, Xiang'An Hospital of Xiamen University, Xiamen, China.
  • Rao H; Peking University Hepatology Institute and Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Beijing, China.
  • Li J; Department of Emergency Medicine, Peking University People's Hospital, Beijing, China.
  • Chen Y; Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
  • Yu B; Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
  • Xu Y; Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
  • Chen H; Peking University Hepatology Institute and Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University People's Hospital, Beijing, China.
  • Gao Z; Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
  • Jiang B; Department of Orthopedics and Trauma, Peking University People's Hospital, Beijing, China.
Front Cell Infect Microbiol ; 11: 768993, 2021.
Article in English | MEDLINE | ID: covidwho-1556329
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shows a high degree of homology with SARS-CoV. They share genes, protein sequences, clinical manifestations, and cellular entry patterns. Thus, SARS research may serve helpful in gaining a better understanding of the current coronavirus disease 2019 (COVID-19) pandemic. Serum antibodies from convalescent patients with SARS collected in 2018 were used to target the recombinant SARS-CoV-2 spike protein via a chemiluminescence microsphere immunoassay. Antibodies of convalescent patients with SARS exhibited serous immune cross-reactivity with the SARS-CoV-2 spike protein. The serous antibodies, excluding S22 of convalescent patients with SARS, did not competitively inhibit the binding of SARS-CoV-2 spike protein to ACE2. T cellular immunity research was conducted in vitro using peripheral blood mononuclear cells (PBMCs) stimulated by pooled peptide epitopes 15 years post-infection. Interferon gamma was detected and the PBMC transcriptomic profile was obtained. The heatmap of the transcriptomic profile showed that mRNAs and circRNAs of the SARS group clustered together after being stimulated by the peptide epitope pool. Differentially expressed mRNAs were most significantly enriched in immunity and signal transduction (P < 0.01). SARS elicits cytokine and chemokine responses, partially consistent with previously published data about COVID-19. Overall, our results indicate that antibodies from convalescent patients with SARS persisted for 15 years and displayed immune cross-reactivity with the SARS-CoV-2 spike protein. The immune status of patients with SARS 15 years post-infection may provide a better understanding of the future immune status of patients with COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukocytes, Mononuclear / COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Front Cell Infect Microbiol Year: 2021 Document Type: Article Affiliation country: Fcimb.2021.768993

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Leukocytes, Mononuclear / COVID-19 Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Front Cell Infect Microbiol Year: 2021 Document Type: Article Affiliation country: Fcimb.2021.768993